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Background: The underlying mechanisms leading to dementia and Alzheimer’s dis-
ease (AD) are unclear. Asymmetric dimethylarginine (ADMA), an endogenous inhibi-
tor of nitric oxide synthase, may be associated with cognitive decline, but
population-based evidence is lacking.
Methods: Change in cognitive performance was assessed in participants of the Aber-
deen Birth Cohort of 1936 using longitudinal Raven’s progressive matrices (RPM)
between 2000 and 2004. Multiple linear regression was used to estimate the associa-
tion between ADMA concentrations in 2000 and change in cognitive performance
after adjustment for potential confounders.
Results: A total of 93 participants had complete information on cognitive perfor-
mance between 2000 and 2004. Mean plasma ADMA concentrations were approxi-
mately 0.4 μmol/L lower in those participants with stable or improved RPM scores
over follow-up compared with participants whose cognitive performance worsened.
In confounder-adjusted analysis, one SD (0.06 μmol/L) increase in ADMA at 63 years
of age was associated with an average reduction in RPM of 1.26 points (95% CI
0.14-2.26) after 4 years.
Conclusion: Raised plasma ADMA concentrations predicted worsening cognitive per-
formance after approximately 4 years in this cohort of adults in late-middle age.
These findings have implications for future research, including presymptomatic diag-
nosis or novel therapeutic targets for dementia and AD.
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1 | INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised
by a rapid decline in cognition in old age, which is distinct from the nor-
mal ageing process. The causes of late onset AD are largely unknown
and despite extensive research, there is still no clear consensus on
blood-based biomarkers or effective treatments.1,2 The vast majority of
research has focused on a set of histopathological hallmarks which are
often present in diseased brains. However, evidence from observational
studies suggests a poor correlation between plaque density and degree
of dementia in AD,3,4 and multiple pharmacological interventions
targeting these histopathological hallmarks have proven ineffective.5
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There is growing observational evidence for an overlap of risk fac-
tors in AD and cardiovascular disease. For example, diabetes is associ-
ated with a 2- to 3-fold increased risk of vascular events6,7 but also a
50% increased risk of dementia8 and a 20% increase in the rate of
cognitive decline.9-11 Furthermore, large genomewide association
studies have confirmed associations between ‘vascular risk’ genes and
the development of AD,12 with the strongest known genetic risk fac-
tor being a mutation in the apolipoprotein E4 gene, which encodes a
cholesterol transporter protein.13 Vascular endothelial dysfunction, an
abnormality that is associated with the presence of virtually all known
cardiovascular risk factors, is frequently seen in AD. Despite this evi-
dence, there is a lack of population-based research investigating the
roles of vascular changes, oxidative stress, lipid metabolism and
inflammation in AD pathogenesis.14,15
Nitric oxide (NO) has an established role as a mediator in the
pathogenesis of cardiovascular disease16 but also potentially in
AD.17,18 Impaired NO release from dysfunctional endothelial cells pre-
cedes reduced blood flow and regional metabolic deficiency. This may
result in hypoxic events, leading to activation of the immune response
and resultant cell death.17 In support of this hypothesis, recent inter-
ventions to increase the concentrations of endogenously produced
NO have halted AD pathogenesis in mice.19 Furthermore, abnormal
NO signalling has been reported in the brains of both human sufferers
and animal models of AD.20,21
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor
of nitric oxide synthase (NOS), an essential enzyme for the synthesis
of NO.17 Therefore, ADMA may play an important pathophysiological
role in the abnormal NO signalling observed in both CVD and AD and
could be a potential target for novel therapeutic interventions.
A number of small-scale studies have investigated the association
between ADMA concentrations and cognitive decline in older
adults.22-25 However, no study has adjusted for childhood intelligence,
which explains up to 50% of cognitive decline in old age.26-28 Investi-
gating the association between ADMA and cognitive decline with full
adjustment for potential confounders could have implications for
presymptomatic diagnosis of AD and may reveal novel drug targets.
This study aims to investigate the relationship between plasma ADMA
concentrations and the change in cognitive performance across
four years in the 1936 Aberdeen Birth Cohort (ABC36) study.
2 | METHODS
2.1 | Study population
The ABC36 is a well-studied cohort population described in greater
depth elsewhere.29,30 Briefly, 506 volunteers were recruited from
Aberdeen in 2000, each of whom were born in 1936 and had com-
pleted the Moray House mental survey (MHT), a measure of cognitive
performance, in 1947. A total of 986 MHT scores matched with
records of local medical practice members. Of these, 647 were invited
to participate in a longitudinal study of cognitive ageing and health, of
which 506 (78%) agreed to participate. Of these, baseline cognitive
assessments were undertaken on 480 (74%) participants who were all
in good health and living independently aged approximately 63 years.
Of these, 246 individuals had complete information on all baseline
assessments, including blood measurements (Supplementary Table 1).
A total of 93 study participants completed all waves (WII and WIII) of
resurvey assessments in 2002 and 2004, aged approximately 65 and
67 years, respectively.
2.2 | Study procedures
Assessment interviews were conducted in three stages, carried out by
a trained research nurse. The first section comprised assessment of
demographic and clinical data, which included smoking and alcohol
history, family history of dementia, diabetes or stroke and a physical
examination including measurement of body mass index (BMI). Writ-
ten informed consent was obtained from all participants at the start of
the interview. All study procedures were approved by the Grampian
Research Ethics Committee (GREC).
Occupation, deprivation scores and years of formal education
were used as a composite measure of socioeconomic status (SES).
Occupation was categorised in accordance with the Standard Occupa-
tional Classification issued by the Scottish Government.31 Each partic-
ipant was given a deprivation code corresponding to the postcode of
their home address in accordance with the Scottish Index of Multiple
Deprivation ranking system.32 During the physical examination, blood
pressure readings were recorded (sitting). Hypertension was identified
when mean systolic pressure was above 144 mmHg or when mean
diastolic pressure was above 94 mmHg. Subjects receiving medica-
tion for the treatment of hypertension were included in the hyperten-
sive category. Subjects were asked to disclose smoking habits into the
following classifications: never smoked, previous smoker and current
Key points
• This cohort study investigated the association between
serum ADMA levels and change in cognitive performance
in late-middle age (from 63 to 67 years) for the first time
using a prospective cohort study de/sign.
• Circulating ADMA levels displayed strong, linear and
inverse associations with cognitive function after 4 years.
Therefore, blood-based ADMA has potential to aid the
early detection of cognitive decline in late-middle age
and must be explored using larger studies.
• These findings suggest a potential role of nitric oxide
impairment in the pathophysiology underlying cognitive
impairment and possible progression to AD, with implica-
tions for presymptomatic diagnosis or novel therapy.
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smoker. As an additional assessment, hippocampal volumes were ana-
lyzed through MRI imaging assessment at WIII. The MR acquisition
procedure has been described in greater depth elsewhere.33
2.3 | Childhood intelligence
All children born in 1936 in Scottish schools were included in a survey
of mental ability on the 4 June 1947, an initiative led by the Scottish
Council for Research in Education. All children took version number
12 of the MHT, comprised of 71 questions with 76 being the maxi-
mum attainable score. The results of this test have been found to
directly correlate with Stanford-Binet IQ scores.34
2.4 | Baseline cognitive ability and follow-up
A measure of cognitive ability was assessed using standard Raven’s
Progressive Matrices (RPM) tests during three waves (WI to WIII) of
assessments in 2000 to 2001, 2002 to 2003 and 2003 to 2004,
respectively. The test is comprised of five sets of 12 questions,
which become increasingly difficult, hence greater cognitive ability
is associated with a higher score.35 For the purposes of this study,
scores from WI and WIII were used to measure cognitive trajecto-
ries, with the difference between the two scores being the primary
outcome measure. For the primary analyses, subjects were grouped
into three categories based on change in cognition from WI to WIII.
Participants were categorised as rapid decliners if their RPM scores
had decreased by 7 points or more from baseline assessment (WI).
Participants were allocated into the slow decline category if WIII
RPM scores had decreased anywhere between 0 and 6 points below
baseline scores. The maintainers and improvers had either
maintained cognitive function or improved their RPM score
between WI and WII assessments.
2.5 | Plasma ADMA levels
Blood samples were taken at baseline (WI) in 2000 and measurement
of serum lipids undertaken. A random subset of blood samples were
centrifuged at 4C for 10 minutes at 2500 rpm to obtain plasma
which was then frozen at −80C. Samples were thawed at a later date
and plasma ADMA concentrations were measured using hydrophilic-
interaction liquid chromatography-electrospray tandem mass spec-
trometry as described previously.36
2.6 | Statistical analysis
To investigate population sample characteristics, chi-square tests and
tests for linearity were employed to compare the means between
each subgroup of cognitive trajectory profile and selected characteris-
tics at baseline. The corresponding significance value for each test
was presented in the results.
The adjusted mean values (and corresponding 95% confidence
intervals) of baseline ADMA were estimated for each category of
change in RPM from baseline to WIII assessment using a direct stan-
dardization technique. The adjusted association between plasma
TABLE 1 Baseline characteristics of study population, by cognitive performance category
Baseline characteristics
Difference in RPM score after 4 years
Ptrend/het AllRapid decliners Slow decliners Maintainers/improvers
Total n (% of 93) 15 (16) 43 (46) 35 (38) 93
Age, years (mean [SD]) 63.3 (0.6) 63.3 (0.6) 63.2 (0.4) .699 63.3 (0.5)
Sex,n (%) .707
Male 6 (40) 26 (60) 19 (54) 51 (55)
Female 9 (60) 17 (40) 16 (46) 42 (45)
Formal education (years), n (%) .891
0–10 8 (53) 27 (63) 22 (63) 57 (62)
11-13 6 (40) 9 (21) 5 (14 20 (21)
>14 1 (7) 7 (16) 8 (23) 16 (17)
Current smoker, % (mean) 26.6% (46) 18.6% (39) 20.0% (41) .588 20.4% (41)
Alcohol consumption, units/week (mean [SD]) 7.1 (8.5) 5.3 (6.9) 5.5 (7.0) .497 5.7 (7.2)
RPM score at first visit (mean [SD]) 41.9 (6.4) 38.4 (8.3) 36.7 (8.5) <.001* 38.3 (8.2)
Childhood MHT score (mean [SD]) 42.9 (10.7) 42.8 (11.8) 47.8 (9.9) .794 44.7 (11.1)
Note: Categories of cognitive performance correspond to the following differences in RPM score between baseline and follow-up assessments: Rapid
decliners = RPM score decrease by ≥7 points; slow decliners = RPM score decrease between 0 and 6 points; maintainers/improvers = RPM score remained
unchanged or increased across follow-up.
Abbreviations: MHT = Moray house test; RPM = Ravens progressive matrix score.
*P < .05 for linear trend.
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ADMA concentrations and change from baseline RPM score to WIII
RPM score was investigated using multiple linear regression analy-
sis. The model was adjusted for gender, smoking status, systolic
blood pressure, SES, RPM score at baseline, childhood mental ability
and hippocampal volume as potential confounding variables. The
results were expressed as beta (β) coefficients and corresponding
95% CI representing the difference in RPM score between WI and
WIII per one SD increasing ADMA at baseline. All variables con-
tained no outliers, and each was tested for homoscedasticity of
residuals, a normal sampling distribution and independence, thereby
meeting the criteria for multiple linear regression analysis. All statis-
tical analyses were conducted using STATA version 16.0 and R
version 3.5.2.
3 | RESULTS
A total of 93 participants with complete information at baseline and
all subsequent assessments contributed to the main analyses
(Table 1). Across the four year follow-up period, the majority of study
participants (n = 43) showed a slow decline in cognitive performance,
15 participants showed a rapid decline, and 35 participants
maintained or improved their cognition scores. On average, partici-
pants were 63.3 (SD 0.5) years at baseline, and just over half of partic-
ipants (55%) were men. Although not statistically significant, a slightly
larger proportion of participants with declining cognitive performance
across follow-up were men (60%). Similarly, prior to confounder
adjustment, no significant differences in baseline age, years of educa-
tion, childhood MHT score, smoking habits, or alcohol consumption
were observed between participants who improved or maintained
their cognitive performance scores. Participants showing a decline in
RPM score from baseline to follow-up had significantly lower baseline
SBP values and raised RPM scores compared with participants who
maintained or improved their RPM score (Table 2). However, baseline
ADMA, DBP, cholesterol concentrations and BMI were similar across
TABLE 2 Body size and biomarker characteristics at baseline assessment, by cognitive performance category
Baseline characteristics
Difference in RPM score after 4 years
Ptrend AllRapid decliners Slow decliners Maintainers/improvers
ADMA, μmol/L (mean [SD]) 0.464 (0.061) 0.458 (0.065) 0.446 (0.065) .807 0.455 (0.064)
BMI, kg/m2 26.0 (4.2) 27.4 (4.6) 26.5 (4.2) .261 26.8 (4.4)
SBP, mm Hg (mean [SD]) 135.3 (26.8) 142.8 (20.8) 147.6 (24.7) .008* 143.4 (23.5)
DBP, mm Hg (mean [SD]) 79.3 (11.4) 78.5 (8.7) 77.5 (10.1) .975 78.3 (9.6)
HDL, mmol/L (mean [SD]) 1.46 (0.37) 1.33 (0.40) 1.45 (0.35) .108 1.39 (0.38)
LDL, mmol/L (mean [SD]) 3.66 (0.83) 3.23 (0.84) 3.43 (0.92) .104 3.37 (0.87)
Nonfasting triglycerides, mmol/L (mean [SD]) 2.03 (1.30) 1.97 (0.92) 2.10 (1.30) .720 2.03 (1.13)
Categories of cognitive performance correspond to the following differences in RPM score between baseline and follow-up assessments: rapid
decliners = RPM score decrease by ≥7 points; slow decliners = RPM score decrease between 0 and 6 points; maintainers/improvers = RPM score remained
unchanged or increased across follow-up.
ADMA = asymmetric dimethylarginine; BMI = body-mass index; DBP = diastolic blood pressure; HDL = high density lipoprotein; LDL = low density lipopro-
tein; SBP = systolic blood pressure.
*P < .05 for linear trend.
F IGURE 1 Association between baseline ADMAacross categories of
cognitive function scores between baseline and 4-year repeat assessment.
Mean values (95%confidence intervals) were adjusted for gender, smoking,
social deprivation, education and hippocampal volume. Areas of point
estimates are inversely proportional to the variance of the coefficient.
Participantswere categorised asmaintainers or improvers if they did not
achieve a lower score atwave III (WIII) comparedwithwave I (WI). Similarly,
participantswere categorised as slowdecliners if they achieved between
1 and7 points below their baseline levels, and rapid decliners if
performance atWIII was greater than 7 points below the baseline RPM
score. The y-axis is standardised to represent ±0.5 SDs from themean
value of ADMA
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RPM performance categories before adjustment for potential
confounders.
In confounder adjusted analysis, ADMA concentrations were nega-
tively and linearly associated with an improvement in cognitive perfor-
mance approximately four years after baseline (Figure 1). On average,
one SD (roughly equivalent to 0.06 μmol/L) increase in ADMA at base-
line was associated with a reduction in cognitive performance score of
1.26 (95% CI 0.14-2.26) points from baseline to WIII assessment.
4 | DISCUSSION
After full adjustment for potential confounders, higher plasma ADMA
concentrations were associated with a decline in cognitive performance
approximately four years later. This finding supports conclusions drawn
from several previous studies.22-25 Poor cognitive performance, in the
absence of a clinical syndrome such as mild cognitive impairment (MCI)
or dementia, is a risk factor for the development of dementia. There-
fore, plasma ADMA concentrations may predict dementia at older age.
4.1 | Comparison with previous observational
evidence
To our knowledge, no study has investigated the prospective association
between ADMA concentrations and cognitive decline trajectories in lon-
gitudinal population studies to date. In a cross-sectional study, mean
plasma ADMA concentrations were approximately 0.1 μmol/L higher
among 80 AD patients compared with 80 matched controls.22 Similarly,
in a smaller case-control study of 25 AD patients and 25 matched con-
trols, plasma ADMA concentrations were approximately 0.4 μmol/L
higher among AD patients vs controls.25 However, beyond matching on
age and sex, these studies were unable to adjust for other important
confounding factors. In the Hunter Community study, a cohort of
483 healthy elderly Australians, participants in the top quarter of ADMA
distribution had 1.82 (95% CI: 1.04-3.18) greater odds of memory
impairment compared to the lowest group after adjusting for age, educa-
tion and sex.23 The Barcelona-AsIA Neuropsychology Study, including
over 740 adults aged 51 to 79 years, reported that higher plasma ADMA
concentrations were associated with a reduction in verbal memory after
adjusting for age, gender, years of education and depressive symp-
toms.24 However, all of these studies were cross-sectional in nature,
which limits the ability to infer causation. Furthermore, we are unable to
rule out the effects of reverse causality (ie, AD patients may have altered
their behavior as a result of the disease, potentially influencing plasma
ADMA levels). A number of studies have reported similar effects of
ADMA concentrations on cognitive deficits in animal models.37
4.2 | Underlying mechanisms
The exact cause of the association between plasma ADMA concentra-
tions and cognitive function is unknown. However, a number of
mechanisms have been suggested previously.38 The observed positive
association may be the result of impaired endothelial-derived NO syn-
thesis, which may influence the onset and progression of cognitive
decline and AD through two main mechanisms: (a) increased athero-
sclerosis and vasoconstriction, leading to subsequent impaired cere-
bral blood flow regulation and cognitive function and (b) enhanced
oxidative stress and reduced neuroprotection of astrocytes.
The proposed theory of ADMA-mediated endothelial dysfunction
and vascular damage is thought to be the result of vasoconstriction
and remodelling which accompanies a reduced availability of NO, thus
favouring atherosclerosis. The resulting impairment of cerebral blood
flow regulation increases the risk of acute ischemic events and sub-
acute or chronic hypoperfusion states, which greatly increase an indi-
vidual’s susceptibility to dementia. The production of NO is known to
maintain synaptic plasticity and contribute to neuroprotection
through restricting the influx of Ca++ and resultant cell death, as well
as activating neuroprotective proteins and important antioxidant pre-
cursors.38 It is also possible that impaired endothelial-derived NO syn-
thesis leads to the build-up of toxic proteins in the brain, leading to
progressive cognitive decline and the onset of AD.18,39
4.3 | Implications of study findings
Given the observed association, and pending further evidence from
large-scale studies, potential clinical uses of ADMA include risk strati-
fication in old age, diagnosis of preclinical AD, or identification of
novel therapeutic targets. Dementia is a progressive debilitating con-
dition, costing an estimated US$800 billion per year globally,40 and
more importantly, costing dementia patients substantial losses in qual-
ity of life for extended periods. The global number of people living
with dementia more than doubled between 1990 and 2016, and the
prevalence is expected to continue rising.41 Once diagnosed, treat-
ment options are severely limited, mostly due to the late onset of
symptoms. Without a breakthrough in early diagnosis and prevention
of the disease, the burden on caregivers and geriatric care services will
continue to increase rapidly.
Importantly, ADMA concentrations can be modulated by pharma-
cological interventions,42 and therefore ADMA may prove valuable as
a future prevention strategy for dementia and AD. Endogenous
enzymes involved in ADMA metabolism have been suggested as a
means for manipulating ADMA levels in vivo. Approximately 80% of
endogenous ADMA is metabolized in intracellular compartments by
dimethylarginine dimethylaminohydrolase (DDAH),43 and, pharmaco-
logical strategies to reduce endogenous ADMA via up-regulation of
DDAH have been previously proposed as a novel treatments for dis-
orders with abnormal NO signalling.44
Various cohort studies have confirmed associations between
higher ADMA concentrations and a number of chronic diseases,
including type 2 diabetes, cardiovascular disease and stroke.45-47 In
addition, a recent review has also highlighted the potential involve-
ment of ADMA in the pathogenesis of other chronic diseases beyond
atherosclerotic diseases, including COPD and depression.48 Together
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with a growing ageing population, the increasing prevalence of
chronic disease risk factors is leading to rapid increases in mul-
timorbidity and polypharmacy. Adverse drug reactions (ADRs) are
themselves a major cause of morbidity, accounting for an estimated
6.5% of unplanned hospital admissions.49 Therefore, given the overlap
of risk factors between AD and other chronic diseases, ADMA could
represent a unified novel pathway for future therapeutics targeted at
a single pathway for chronic disease prevention.
4.4 | Future research directions
Given the potential for impact, there is a clear rationale for continued
research into the association between plasma ADMA and dementia.
Large-scale, robust prospective cohort studies are required, with long
follow-up, standardised outcome assessments and repeat exposure
measurements. Ideally, to establish risk factors, follow-up should
cover the window of opportunity to intervene by assessment of
dementia risk factors in middle age. Furthermore, the availability of
genetic information would allow for the assessment of causality
underlying observational associations. Following on from this, phar-
macological strategies are required to reveal whether the change in
ADMA concentration mediates any beneficial effect of these inter-
ventions on clinical end-points such as cognitive function. Encourag-
ingly, studies have confirmed the pharmacokinetics and the
short-term safety of arginine metabolite supplementation.42,50 How-
ever, intervention studies investigating clinical end-points, for exam-
ple, cardiovascular morbidity and mortality, are eagerly awaited.
4.5 | Strengths and limitations
This study presents with a number of strengths. First, the prospective
study design enabled us to study the association between ADMA con-
centrations and change in cognition for the first time, which has not
been conducted to date. In addition, as discussed previously, child-
hood intelligence is one of the strongest predictors of cognition in old
age,26-28 and therefore the availability of childhood intelligence in
ABC36 offered an unparalleled opportunity to study the longitudinal
cognitive ageing, independent of childhood cognition. Furthermore, as
all participants were born within the same year, any observed changes
were unlikely to be the result of differences in age, or cohort effects,
which is a common challenge when interpreting epidemiological evi-
dence. Another important strength is the use of hydrophilic-
interaction liquid chromatography-electrospray tandem mass
spectrometry techniques for ADMA measurements. Since these are
gold-standard techniques, the effect of measurement error in the
exposure is reduced in the current analyses.
However, when interpreting the results presented here, it is impor-
tant to consider a number of potential limitations. First, the sample size
is relatively small, with 15 participants showing evidence of rapid cogni-
tive decline after four years. Therefore, the results of this study are
hypothesis-generating, and they should be interpreted with caution.
Additional prospective studies with larger sample sizes and longer dura-
tions of follow-up are required to confirm the association between
plasma ADMA and a change in cognitive performance. Second, only a
single measure of plasma ADMA per participant was used in this investi-
gation. Although plasma ADMA is thought to remain relatively stable,
there are known physiological conditions whereby measured ADMA
concentrations may be misrepresentative of normal circulating
levels.51,52 Also, although studies have reported that cerebrospinal fluid
ADMA concentrations are lower than plasma ADMA concentrations in
AD patients, no information is available regarding the strength of the
correlation between plasma and cerebrospinal fluid concentrations.53
Therefore, additional research is required to investigate whether periph-
eral ADMA concentrations adequately reflect the concentrations of this
metabolite in the central nervous system.
A common source of bias in longitudinal studies of cognitive age-
ing is the retention of volunteer participants, as participants who drop
out tend to score lower during initial cognitive tests, a group who are
at greater risk of dementia.50 With this knowledge, practitioners may
have inflicted bias into the present study through inviting rapid
decliners back for follow-up assessments earlier than nondecliners.
Moreover, refusal to participate was significantly associated with low
childhood mental ability (MHT) scores (P < .05), reported as a source
of bias elsewhere.54
Furthermore, although we adjusted for multiple important factors,
it is not possible to rule out the effects of residual confounding.
Importantly, no measure of renal function was included in the ana-
lyses. ADMA is removed from the body through a combination of
intracellular metabolism and renal excretion, and hence renal function
is an important confounding variable, which would explain some of
the variance in plasma ADMA levels. However, this may have been
less important in this present study since renal function is generally
not altered in healthy individuals at age 63 years. Of these limitations,
some were unavoidable consequences of observational research.
4.6 | Conclusion
In summary, the results from this study suggest that ADMA concen-
trations are associated with cognitive decline in older age. Therefore,
plasma ADMA, or correlates thereof, may be involved in the patho-
genesis underlying cognitive decline and progression to AD. However,
larger studies investigating this association are warranted. Possible
future implications include the discovery of novel drug targets or pres-
ymptomatic biomarkers for AD.
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